BioSpace News Archive

CVRx, Inc. (“CVRx”) today announced its financial and operating results for the fourth quarter and full year of 2023, and affirmed its 2024 business outlook.

PTC Therapeutics, Inc. announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency issued a negative opinion following the re-examination procedure for the conditional marketing authorization of Translarna™.

Titan Pharmaceuticals, Inc. announced that by letter dated January 24, 2024, the Company was notified by The Nasdaq Stock Market LLC that the Company has regained compliance with the minimum $1.00 bid price requirement and otherwise satisfies all applicable criteria for continued listing on The Nasdaq Capital Market.

BrightSpring Health Services, Inc. (“BrightSpring” or “BrightSpring Health Services”) today announced the pricing of an initial public offering of 53,333,334 shares of its common stock at $13.00 per share and a concurrent offering of 8,000,000 of its 6.75% tangible equity units (“Units”), with a stated amount of $50.00 per Unit.

ArriVent BioPharma, Inc. announced the pricing of its upsized initial public offering of 9,722,222 shares of its common stock at a public offering price of $18.00 per share.

Taro Pharmaceutical Industries Ltd. provided unaudited financial results for the quarter and nine months ended December 31, 2023.

Vanda Pharmaceuticals Inc. announced that the U.S. Patent and Trademark Office has issued a notice of allowance for its PONVORY® patent application, number 17/962,968, covering methods for reducing clinical management events before or during the treatment of multiple sclerosis and methods for reinitiating treatment after missed doses.

Repare Therapeutics Inc. announced today that, under its worldwide license and collaboration agreement with Roche for the development and commercialization of camonsertib, it has earned a $40 million milestone payment from Roche.

Cyprium Partners is pleased to announce it has completed its 100 th platform investment, providing debt and equity to OneroRx Inc, headquartered in West Des Moines, Iowa.

Organovo Holdings, Inc. (Nasdaq: ONVO) today announced the presentation of preclinical data related to the company’s FXR314 development program in its proprietary 3D human tissue models of Crohn’s disease and ulcerative colitis at the Crohn’s and Colitis Congress being held January 25-27, 2024 in Las Vegas, Nevada.